Geri
Poolbeg Pharma PLC (POLBF) Fiyatı
POLBF Hisse Senedi Fiyat Grafiği
POLBF Kazanmak
Poolbeg Pharma PLC
$0.04
0%
$0
Kapanışta: Jan 16, 16:00:00 GMT-5
$0.04
0%
$0
Sonrası Piyasa: Jan 16, 20:00:00 GMT-5
Earnings FAQ
POLBF'ün son EPS'si beklentilerle karşılaştırıldığında nasıldı?
Poolbeg Pharma PLC POLBF'ün son çeyrekteki geliri nasıl performans gösterdi?
Poolbeg Pharma PLC'in gelir tahmini nedir?
Poolbeg Pharma PLC'in kazanç kalite puanı nedir?
Poolbeg Pharma PLC kazançlarını ne zaman rapor eder?
Poolbeg Pharma PLC'in beklenen kazançları nelerdir?
Poolbeg Pharma PLC kazanç beklentilerini aştı mı?
Önemli İstatistikler
Önceki Kapanış
$0.0425
Açılış fiyatı
$0.196
Günün Aralığı
$0.0425 - $0.196
52 haftalık aralık
$0.042 - $0.196
İşlem hacmi
460
Ort.Hacim
0
EPS (TTM)
-0.02
Dividend yield
--
Piyasa Değeri
$29.6M
POLBF nedir?
Poolbeg Pharma Plc is a clinical-stage biopharmaceutical company, which focuses on the development of innovative medicines to address unmet medical needs. The firm is focused on the development of medicines to address unmet medical needs. Its clinical programmes target addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions, such as obesity with the development of an oral encapsulated glucagon-like peptide (GLP-1R) agonist. Its pipeline includes POLB 001 Oncology, POLB 001 Influenza, AI Programmes and Oral Encapsulated GLP-1programme. POLB 001 is an orally delivered p38 MAP Kinase inhibitor being developed for the prevention of CRS associated with Bispecific Antibodies and CAR T immunotherapy treatments in cancer. The company uses artificial intelligence to identify infectious disease drug targets & treatments. The Oral Encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients using Generally Regarded as Safe (GRAS) components.
Özellikler
Ticaret Stratejileri
Kaynaklar
© 2025 Finture Development Limited. All rights reserved